Hypnosis may be beneficial in reducing hot flashes in breast cancer survivors, according to research published online Sept. 22 in the Journal of Clinical Oncology
Hypnosis may be beneficial in reducing hot flashes in breast cancer survivors, according to research published online Sept. 22 in the Journal of Clinical Oncology.
Gary Elkins, PhD, of Baylor University in Waco, Texas, and colleagues analyzed data from 60 women with a history of breast cancer but no detectable disease and a history of at least 14 hot flashes per week for at least a month. Women were randomized to receive five weekly hypnosis sessions or no treatment, and 51 subjects completed the study.
In the treatment arm, participants’ hot flash scores--a measure of frequency and average severity--fell 68 percent from baseline to the end of the study, and the no-treatment group showed little improvement, the researchers report. The hypnosis group also showed significant improvement in anxiety, sleep, and interference of hot flashes with daily activities.
“Mind-body and behavioral approaches to reducing vasomotor symptoms are attractive interventions for survivors of breast cancer. They convey minimal or no risk, have no adverse effects, and are generally low cost,” writes Nancy E. Avis, PhD, of Wake Forest University in Winston-Salem, N.C., in an accompanying editorial. “Adverse events and adverse effects such as vasomotor symptoms are the main reason for non-adherence to endocrine treatment, and interventions aimed at reducing adverse effects are needed. Mind-body approaches provide potentially safe and effective interventions to reduce vasomotor symptoms and are particularly appropriate for survivors of breast cancer.”
Elkins G, Marcus J, Stearns V, et al. Randomized trial of a hypnosis intervention for treatment of hot flashes among breast cancer survivors. J Clin Oncol. 2008:1;26:5022-5026.
Severe maternal morbidity linked to mental health risks post-delivery
April 26th 2024A recent study revealed that severe maternal morbidity during pregnancy increases the likelihood of mental health hospitalizations or emergency department visits up to 13 years post-delivery, emphasizing the need for mental health screening.
Read More
FDA approves updated label for Biktarvy against HIV-1
April 26th 2024Gilead Sciences has announced FDA approval of an updated Biktarvy label, showcasing safety and efficacy data from a phase 1b trial, positioning it as a pivotal treatment option for pregnant individuals with HIV-1 and suppressed viral load.
Read More
No link found between antenatal corticosteroids and child neurodevelopment
April 25th 2024A recent study found no link between antenatal corticosteroid administration and adverse neurodevelopmental outcomes in children aged 6 years or older, offering reassurance for late preterm delivery practices.
Read More